Antibody and TLR7 Agonist Delay Viral Rebound in SHIV-Infected Monkeys

The latent viral reservoir is the critical barrier for the development of an HIV-1 cure. Previous studies have shown that potent HIV-1 Env-specific broadly neutralizing antibodies (bNAbs) administered at the time of antiretroviral therapy (ART) discontinuation can exert direct antiviral effects, but...

Descripción completa

Detalles Bibliográficos
Autores principales: Borducchi, Erica N., Liu, Jinyan, Nkolola, Joseph P., Cadena, Anthony M., Yu, Wen-Han, Fischinger, Stephanie, Broge, Thomas, Abbink, Peter, Mercado, Noe B., Chandrashekar, Abishek, Jetton, David, Peter, Lauren, McMahan, Katherine, Moseley, Edward T., Bekerman, Elena, Hesselgesser, Joseph, Li, Wenjun, Lewis, Mark G., Alter, Galit, Geleziunas, Romas, Barouch, Dan H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237629/
https://www.ncbi.nlm.nih.gov/pubmed/30283138
http://dx.doi.org/10.1038/s41586-018-0600-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237629/
https://www.ncbi.nlm.nih.gov/pubmed/30283138
http://dx.doi.org/10.1038/s41586-018-0600-6

Ejemplares similares